WO2005027951B1 - Method for controlling angiogenesis in animals - Google Patents

Method for controlling angiogenesis in animals

Info

Publication number
WO2005027951B1
WO2005027951B1 PCT/US2004/030331 US2004030331W WO2005027951B1 WO 2005027951 B1 WO2005027951 B1 WO 2005027951B1 US 2004030331 W US2004030331 W US 2004030331W WO 2005027951 B1 WO2005027951 B1 WO 2005027951B1
Authority
WO
WIPO (PCT)
Prior art keywords
modified pectin
galectin
organism
compound
modified
Prior art date
Application number
PCT/US2004/030331
Other languages
French (fr)
Other versions
WO2005027951A1 (en
Inventor
Yan Chang
Vodek Sasak
Original Assignee
Glycogenesys Inc
Yan Chang
Vodek Sasak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycogenesys Inc, Yan Chang, Vodek Sasak filed Critical Glycogenesys Inc
Priority to EP04788790A priority Critical patent/EP1684779A1/en
Priority to JP2006527020A priority patent/JP2007521106A/en
Publication of WO2005027951A1 publication Critical patent/WO2005027951A1/en
Publication of WO2005027951B1 publication Critical patent/WO2005027951B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Disease conditions which are dependent upon or moderated by angiogenesis are controlled by the use of a therapeutic material which interacts with cell surface galectins. Particular therapeutic materials comprise a polymeric backbone having side chains terminating in a sugar dependent therefrom. Disclosed are specific therapeutic materials in which the polymeric backbone is based upon polygalacturonic acid, and the side chains terminate in arabinose or galactose.

Claims

AMENDED CLAIMS [received by the International Bureau on 11 April 2005 (11.04.2005); original claims 2-11 amended; remaining claims unchanged (2 pages)]
1. An implantable device having a surface, wherein the surface bears a coating comprisin a fherapeutically effective amount of a compound that binds to a galectin.
2. The device of claim 1, wherein said compound binds to galectin-1 or galectin-3.
3. The device of claim 1 or 2, wherein said compound comprises a partially demethoxylated polygalacturonic acid which is interrupted with rhamnose residues.
4. The device of any preceding claim, wherein said compound comprises a substantially demethoxylated polygalacturonic acid which is interrupted with rhamnose residues.
5. Tire device.of any preceding claim, wherein said compound comprises a polymeric backbone having side chains dependent therefrom, said side chains being terminated t) a galactose or arabinose unit,
6. The device of any preceding claim, wherein said compound comprises a modified pectin.
7. The device of claim 6, wherem said modified pectin comprises a pH modified pectin.
S. The device of claim 6, wherein said modified pectin comprises an enzymatically modified pectin.
9. The device of claim 6, wherein said modified pectin comprises a thermally modified pectin.
AMENDED SHEET (ARTICLE 19)
33
10. The device of claim 6. wherein said modified pectin comprises a modified citrus pectin.
11. The device of any of claims 6-10, wherem said modified pectin has a molecular weight in the range of 1-150 kilodalton.
12. A method for inhibiting angiogenesis in an organism, comprising implanting into said organism the device of any of claims 1-11.
13. The method of claim 12, wherein said galectin is present on the cell surface of a tissue of said organism.
14. A method for treating or inhibiting inflammation in an organism, comprising conjointly administering to the organism a therapeutically effective amount of a compound that binds to a galectin and an anti-inflammatory agent
15. The method of claim 147 wherein the anti-inflammatory agent is selected from antibiotics, antivirals, antifimgals, antiparasitics, aπtiphlogistics, and anu'oxidants.
AMENDED SHEET (ARTICLE 19)
34
PCT/US2004/030331 2003-09-16 2004-09-16 Method for controlling angiogenesis in animals WO2005027951A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04788790A EP1684779A1 (en) 2003-09-16 2004-09-16 Method for controlling angiogenesis in animals
JP2006527020A JP2007521106A (en) 2003-09-16 2004-09-16 Methods for controlling angiogenesis in animals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/665,055 2003-09-16
US10/665,055 US20040121981A1 (en) 2001-11-21 2003-09-16 Method for controlling angiogenesis in animals

Publications (2)

Publication Number Publication Date
WO2005027951A1 WO2005027951A1 (en) 2005-03-31
WO2005027951B1 true WO2005027951B1 (en) 2005-05-26

Family

ID=34375833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/030331 WO2005027951A1 (en) 2003-09-16 2004-09-16 Method for controlling angiogenesis in animals

Country Status (5)

Country Link
US (1) US20040121981A1 (en)
EP (1) EP1684779A1 (en)
JP (1) JP2007521106A (en)
CN (1) CN1882350A (en)
WO (1) WO2005027951A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020027A1 (en) * 2004-07-14 2006-02-23 Glycogenesys, Inc. Composition and method for treating hyperproliferative diseases
EP2420239B1 (en) * 2007-04-13 2015-01-14 Southern Research Institute Clomipramine as anti-angiogenic agent
JP6133894B2 (en) 2011-12-28 2017-05-24 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Composition of novel glycopharmaceuticals for treatment of human diseases
MX2014014979A (en) 2012-06-06 2015-06-17 Galectin Therapeutics Inc Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase.
DK2900061T3 (en) 2012-09-17 2020-03-02 Galectin Therapeutics Inc PROCEDURE FOR ENHANCING SPECIFIC IMMUNTERPRISES IN CANCER TREATMENT
JP6055928B2 (en) 2012-10-10 2016-12-27 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Galactose branched carbohydrate compounds for the treatment of diabetic nephropathy and related disorders
CA2926480A1 (en) * 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
US11020478B2 (en) 2013-11-27 2021-06-01 Inis Biotech Llc Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment
US10294295B2 (en) * 2013-11-27 2019-05-21 Inis Biotech Llc Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment
CA3102155A1 (en) 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435141D1 (en) * 1993-07-19 2008-10-30 Angiotech Pharm Inc Anti-angiogenic agents and methods of use
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5595784A (en) * 1995-08-01 1997-01-21 Kaim; Robert Titanium nitride and multilayers formed by chemical vapor deposition of titanium halides
US5681923A (en) * 1995-10-06 1997-10-28 Platt; David Tumor derived carbohydrate binding protein
US6632797B2 (en) * 1996-06-24 2003-10-14 Matti Siren Method of treating angiogenesis
AU6141498A (en) * 1997-02-04 1998-08-25 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
CA2279791C (en) * 1998-08-14 2011-11-08 Marcus B. Gohlke Dietary supplement combining colostrum and lactorferrin in a mucosal delivery format
US6500807B1 (en) * 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
SE0100172D0 (en) * 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US6890906B2 (en) * 2001-11-21 2005-05-10 Glycogenesys, Inc. Method for controlling angiogenesis in animals

Also Published As

Publication number Publication date
EP1684779A1 (en) 2006-08-02
CN1882350A (en) 2006-12-20
US20040121981A1 (en) 2004-06-24
JP2007521106A (en) 2007-08-02
WO2005027951A1 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
WO2005027951B1 (en) Method for controlling angiogenesis in animals
Zhong et al. Biodegradation of hyaluronic acid derivatives by hyaluronidase
Aravamudhan et al. Natural polymers: polysaccharides and their derivatives for biomedical applications
Hon Chitin and chitosan: medical applications
EP0954323B1 (en) Pharmaceutical compositions comprising a mixture of autocross-linked hyaluronic acid and nonautocross-linked hyaluronic acid and their use for the treatment of arthropathies
Kofuji et al. Preparation and evaluation of a novel wound dressing sheet comprised of β-glucan–chitosan complex
FI94766C (en) Process for the preparation of new therapeutically useful complete and partial esters of hyaluronic acid and their salts
US5908836A (en) Protecting skin from radiation damage using sulphated sugars
JP6517141B2 (en) Galacto-rhamnogalacturonate compositions for treating diseases associated with highly inducible nitric oxide synthase
EP0640346A1 (en) Uses of sulphated sugars against inflammation
EP2025687A1 (en) Process for the preparation of heparanase-inhibiting sulfated hyaluronates and products obtained thereby
JP2004536825A5 (en)
WO2003000195A2 (en) Method and material for treating immune diseases
CA2519797A1 (en) Low molecular weight hyaluronic acid for the treatment of nerve damage
US8513407B2 (en) Process for the preparation of N-acyl-(epi)K5-amine-O-sulfate-derivatives and products thus obtained
MXPA04004873A (en) Method for controlling angiogenesis in animals.
EP1644054B1 (en) Coating system for implants for increasing tissue compatibility
KR20160105969A (en) Derivatives of n-desulfated glucosaminoglycans and use as drugs
CA2489866A1 (en) Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
US10857176B2 (en) Composition comprising polyglucosamine-glyoxylate solutions mixed with hyaluronan
RU2642612C2 (en) Complexes based on chondroitin for cutaneous absorption
CA2020199C (en) Uses of sulphated sugars
WO2015013821A1 (en) Composition comprising polyglucosamine-glyoxylate solutions mixed with hyaluronan
CN111588731A (en) Composition for wound healing and its production method and use
CN114716578B (en) Preparation method and application of soluble euglena polysaccharide

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480033662.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20050411

WWE Wipo information: entry into national phase

Ref document number: 2006527020

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004788790

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004788790

Country of ref document: EP